[Frontiers in Bioscience S3, 1133-1146, June 1, 2011]

A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy

Jose M. Gonzalez1, 3, Davinia Pla1, Dolores Perez-Sala2, Vicente Andres3

1Laboratory of Vascular Biology, Department of Molecular and Cellular Pathology and Therapy, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas (CSIC), Valencia, Spain, 2 Chemical and Physical Biology Department, Centro de Investigaciones Biologicas, CSIC, Madrid, Spain, 3Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Department of Epidemiology, Atherothrombosis and Cardiovascular Imaging, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain


1. Abstract
2. The nuclear lamina
3. Synthesis and post-translational processing of lamin A and C
4. Laminopathies
5. Hutchinson-Gilford progeria syndrome and restrictive dermopathy
6. Mouse models of HGPS and RD
7. Studies with cells from HGPS and RD patients
8. Gene therapy strategies for the treatment of progeria
9. Farnesyltransferase inhibitors as therapeutic agents for the treatment of progeria syndromes
10. Additional therapeutic strategies to treat HGPS
11. Concluding remarks
12. Acknowledgement
13. References


Lamin A and lamin C (A-type lamins, both encoded by the LMNA gene) are major components of the mammalian nuclear lamina, a complex proteinaceous structure that acts as a scaffold for protein complexes that regulate nuclear structure and function. Abnormal accumulation of farnesylated-progerin, a mutant form of prelamin A, plays a key role in the pathogenesis of the Hutchinson-Gilford progeria syndrome (HGPS), a devastating disorder that causes the death of affected children at an average age of 13.5 years, predominantly from premature atherosclerosis and myocardial infarction or stroke. Remarkably, progerin is also present in normal cells and appears to progressively accumulate during aging of non-HGPS cells. Therefore, understanding how this mutant form of lamin A provokes HGPS may shed significant insight into physiological aging. In this review, we discuss recent advances into the pathogenic mechanisms underlying HGPS, the main murine models of the disease, and the therapeutic strategies developed in cellular and animal models with the aim of reducing the accumulation of farnesylated-progerin, as well as their use in clinical trials of HGPS.